Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$11.00 USD
+1.80 (19.57%)
Updated Nov 7, 2024 04:00 PM ET
Pre-Market: $11.07 +0.07 (0.64%) 9:26 AM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EBS 11.00 +1.80(19.57%)
Will EBS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EBS
New Strong Buy Stocks for November 7th
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates
Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades
Other News for EBS
Gold Gains 1%; Halliburton Posts Weak Q3 Results
Emergent BioSolutions rises 31.2%
Qualcomm, Moderna report quarterly beats: Morning Buzz
Qualcomm, Moderna report quarterly beats: Morning Buzz
Emergent BioSolutions rises 31.2%